Stock Events

Stock Events

IO Biotech

$0

51

+$0+1.67% Friday 13:30

Statistics

Day High

0

Day Low

0

52W High

2.4

52W Low

0

Volume

247,594

Avg. Volume

-

Mkt Cap

219,444.44

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

19MayExpected

Q2 2024

Q3 2024

Q1 2025

Q2 2025

Q3 2025

Q4 2025

Next

-0.4

-0.3

-0.2

-0.1

Expected EPS

-0.1

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2020

2021

2022

2023

2024

0Revenue

-190.98MNet Income

Analyst Ratings

0.5Average Price Target

The highest estimate is 0.50.
From 1 ratings within the last 6 months. This is not an investment recommendation.

Buy

0%

Hold

100%

Sell

0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IOBT. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

BioNTech SE is a competitor because it also focuses on developing immunotherapies for cancer and other serious diseases, similar to IO Biotech's focus on novel immune-modulating cancer therapies.

Moderna, Inc. is involved in creating mRNA-based therapies, including cancer vaccines, which puts it in direct competition with IO Biotech's immunotherapy research.

Novavax, Inc. competes in the development of vaccines for serious infectious diseases but its technology and approach to stimulating immune responses can be seen as competitive to IO Biotech's work in cancer immunotherapy.

Gilead Sciences

Gilead Sciences, Inc. has a broad portfolio including oncology, making it a competitor due to its involvement in developing treatments for cancer, similar to IO Biotech's focus.

Amgen Inc. is a biotechnology company with efforts in oncology and therapeutics that could compete with IO Biotech's cancer immunotherapy products.

Pfizer Inc. has a diverse range of biopharmaceutical products, including cancer treatments, making it a competitor in the oncology space alongside IO Biotech.

Bristol-Myers Squibb

Bristol-Myers Squibb Company is heavily involved in cancer research and drug development, positioning it as a competitor to IO Biotech in the oncology market.

Merck & Co., Inc. is a leading pharmaceutical company with a strong emphasis on cancer treatments, including immunotherapy, making it a direct competitor to IO Biotech.

Roche Holding AG engages in the research and development of medical drugs, including cancer immunotherapies, which competes with IO Biotech's focus area.

AstraZeneca PLC is involved in the discovery and development of new cancer treatments, including immunotherapies, making it a competitor in the same field as IO Biotech.

About

IO Biotech, Inc., a clinical-stage biopharmaceutical company, develops immune-modulating cancer therapies based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive proteins, such as Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 2 clinical trial to treat melanoma, as well as in phase 1 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.

Show more...

CEO

Dr. Mai-Britt Zocca Ph.D.

Employees

80

Country

United States

ISIN

US4497781090

Listings

0 Comments

Share your thoughts

FAQ

What is IO Biotech stock price today?▼

The current price of IOBT is $0 USD — it has increased by +1.67% in the past 24 hours. Watch IO Biotech stock price performance more closely on the chart.

What is IO Biotech stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange IO Biotech stocks are traded under the ticker IOBT.

Is IO Biotech stock price growing?▼

IOBT stock has fallen by -1.61% compared to the previous week, the month change is a -50.81% fall, over the last year IO Biotech has showed a -99.75% decrease.

What is IO Biotech market cap?▼

Today IO Biotech has the market capitalization of 219,444.44

What is IO Biotech revenue for the last year?▼

IO Biotech revenue for the last year amounts to 0 USD.

What is IO Biotech net income for the last year?▼

IOBT net income for the last year is -190.98M USD.

How many employees does IO Biotech have?▼

As of May 26, 2026, the company has 80 employees.

In which sector is IO Biotech located?▼

IO Biotech operates in the Health & Wellness sector.

When did IO Biotech complete a stock split?▼

IO Biotech has not had any recent stock splits.

Where is IO Biotech headquartered?▼

IO Biotech is headquartered in Copenhagen, United States.